Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$679.9M
165M shares
52-week range
$0.67 – $5.78
71% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.36%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $346.6M | $428.4M | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | $296.2M |
| Cost of revenue | $32.8M | $135.4M | $3.1M | $70.4M | $1.4M | $6.1M | $7.6M | $0 |
| Gross profit | $313.9M | $293.0M | $386.4M | $343.3M | $409.2M | $436.6M | $343.9M | $296.2M |
| Gross margin | 90.6% | 68.4% | 99.2% | 83.0% | 99.7% | 98.6% | 97.9% | 100.0% |
| R&D | $166.5M | $122.2M | $88.1M | $70.4M | $44.3M | $116.1M | $111.4M | $95.1M |
| Operating income | −$238.9M | $120.1M | $142.9M | $232.3M | $250.3M | −$945.4M | $93.1M | $118.8M |
| EBITDA | −$144.5M | $128.6M | $141.9M | $233.7M | $261.4M | $197.4M | $97.7M | $104.7M |
| Net income | −$282.4M | $21.5M | $106.2M | $528.4M | $175.1M | −$1.00B | $880.0K | $24.0M |
| Net margin | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
| EPS (diluted) | -1.85 | -0.10 | 0.66 | 3.21 | 0.96 | -6.45 | 0.01 | 0.15 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $462M | $1.18 | $1.16–$1.19 | 1 |
| 2027 | $481M | $1.24 | $1.22–$1.25 | 2 |
| 2028 | $493M | $1.41 | $1.39–$1.43 | 1 |
| 2029 | $249M | $0.56 | $0.55–$0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
www.ironwoodpharma.comNo one on the platform currently holds IRWD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 8,061,073 | $28.3M |
No one on the platform has traded IRWD yet.
| $420M |
| — |
| CLLSCellectis S.A. | $2.94 | +3.89% | $295M | — |
| GNLXGenelux Corporation | $2.90 | +1.05% | $109M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at NaN× earnings vs its 11.6× historical median P/E.
Fair value ≈ $-2.31 · price $4.30 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$IRWD two and a half billion dollars…going once…going twice..👨⚖️
View on StockTwits ↗$IRWD What is it going to be, Mr. Tuba? SIVs wrapped up. "First Patient Dosed" or "First Site Activated", clinical trial registry listing appears? Or will it be the great Macedonian hero's favorite flavor, $TAK
View on StockTwits ↗This can become a great week for $IRWD An average of $2 never felt this good! Drop some news guys!
View on StockTwits ↗$IRWD right after ABBV bought Apogee for $11 B over a week ago its SP appreciated for about 15% in a week reaching new historical highs. Adding IRWD for $2 B is guaranteed for another $500M Linzess revenue per yr plus the great potential in APRA approval in 2027. The peak APRA revenue estimated for $800M. The $2 B deal for IRWD might not look funcy & sexy like Apogee deal but GI sector brings in solid long term profits.
View on StockTwits ↗$IRWD Things I’d like to see wrapped up immediately: 1. The Nancy Guthrie case. 2. The Russia/Ukraine war. 3. The USA/Iran conflict. 4. An IRWD announcement. 5. TikTok ownership. 6. Mortgage rates under 6%. 7. Taylor & Travis finally getting married. Not asking for much.
View on StockTwits ↗$IRWD Calling it. Big news will drop between Monday 6/29 - Wednesday 7/1. Off to Ogunquit. Have a great weekend.
View on StockTwits ↗$IRWD Movie that reflects Ironwood: Spaceballs. “Ironwood board prepares to unleash intergalactic shareholder value.”
View on StockTwits ↗$IRWD announce an acquisition with a big fat premium on Monday, that will make the 250th independence anniversary even more special, Tommy man 🎉
View on StockTwits ↗$IRWD Latest SI Needs to cut it half otherwise Shorts are too comfortable here.
View on StockTwits ↗$IRWD 5 days left until the end of Q2 and we haven’t heard anything about the Phase III sites other than that they’re going to be ready. That’s really frustrating. Im not raining on anyone’s parade here, but Abbvie has really no reason to buy this stock if Apra isn’t going anywhere. They have a lock on the Linzess money and there’s no real benefit to them to acquire if Apra isn’t making any real noise.
View on StockTwits ↗$IRWD Submit a picture or gif that best represents your opinion of Ironwood from the top down as an organization. I’ll go first: Kingpin circa 1996. And shareholders are poor ol’Woody.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.